ArticleThe patient2026
PAIRED: Quantitative and Qualitative PAtIent-Reported Experiences and perceiveD Benefit of Treatment with Dolutegravir/Lamivudine in the United States.
Article in The patient, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Narrative Review of Two-Drug Regimens in Modern HIV Care: Driving Innovation, Flexibility, and Quality of Life.Infectious diseases and therapy · 2026Review
- Real-world experience of Dolutegravir/Lamivudine for rapid initiation of antiretroviral therapy among treatment-naïve HIV-1-infected adults in China: a multicenter retrospective study.Frontiers in medicine · 2026Article
- PROs Assessment in Dual (Either Oral or Injectable) Antiretroviral Regimen in People with HIV: A Narrative Review.Viruses · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUnderstanding the treatment experiences and satisfaction of people with HIV using two-drug regimens, including dolutegravir/lamivudine (DTG/3TC), is crucial to assess ongoing needs and meet Ending the HIV Epidemic goals.
methodsPAIRED is a mixed-methods study comprising a quantitative cross-sectional survey (using validated instruments to assess treatment satisfaction, adherence, and health-related quality of life [QOL]) and qualitative interviews. Adults in the USA who switched to DTG/3TC while virologically suppressed and had been using DTG/3TC for ≥ 3 months were eligible. All participants were surveyed, and a sub-set participated in in-depth interviews. Thematic analysis was performed to discern overarching interview themes.
resultsOverall, 474 participants completed the survey (assigned female sex at birth, 31%; non-white, 48%; aged ≥ 50 years, 50%); 20 of them participated in qualitative interviews. Treatment satisfaction, adherence, and QOL scores were high. Six themes were extracted from interviews: (1) fewer drugs are important in HIV treatment because of associated reductions in long-term drug exposure and perceived risk of toxicity; (2) high DTG/3TC satisfaction is largely due to achieved expectations regarding efficacy and safety; (3) DTG/3TC simplicity and convenience enable more freedom and autonomy; (4) treatment advancements led to HIV no longer being a "death sentence"; (5) managing HIV is no longer the main concern relative to other health conditions; and (6) some HIV unmet needs remain.
conclusionsA large representative population with HIV had primarily positive experiences and few needs after switching to DTG/3TC. These data complement clinical trial data and support DTG/3TC effectiveness and tolerability in real-world settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.